nileshnz
28-07-2020, 08:46 PM
Another new IPO, sold by Bell Potter, to list on ASX mid AUG 2020. Issued at $0.73, looks promising. I connected with Bell Potter who said it has closed now so I cannot invest anymore. Has anyone invested in this one ? Could do well, just like AROA BIO (ARX.ASX)
https://smallcaps.com.au/4dmedical-asx-ipo-commercialise-lung-imaging-technology-united-states/
4DMedical launches IPO to commercialise lung imaging technology in the United States
A month away from hitting the ASX, 4DMedical has its sights set on the United States and its spiralling COVID-19 situation as a target market for its lung imaging technology.
The Australian medtech is developing a patented X-ray imaging platform, XV Technology, that scans a patient’s respiratory system to help improve the ability of physicians to diagnose and manage lung diseases.
The company has announced an initial public offering (IPO) to raise $55.8 million through the issue of 76.43 million shares priced at $0.73 each. This indicates a market capitalisation of $193 million at the offer’s completion.
Funds raised will mostly be used for marketing, operating expenditure, product research and development, as well as sales and distribution in the US.
The offer closes on 10 August with 4DMedical anticipating commencement of trading on the ASX under the ticker code ‘4DX’ on 14 August 2020.
https://smallcaps.com.au/4dmedical-asx-ipo-commercialise-lung-imaging-technology-united-states/
4DMedical launches IPO to commercialise lung imaging technology in the United States
A month away from hitting the ASX, 4DMedical has its sights set on the United States and its spiralling COVID-19 situation as a target market for its lung imaging technology.
The Australian medtech is developing a patented X-ray imaging platform, XV Technology, that scans a patient’s respiratory system to help improve the ability of physicians to diagnose and manage lung diseases.
The company has announced an initial public offering (IPO) to raise $55.8 million through the issue of 76.43 million shares priced at $0.73 each. This indicates a market capitalisation of $193 million at the offer’s completion.
Funds raised will mostly be used for marketing, operating expenditure, product research and development, as well as sales and distribution in the US.
The offer closes on 10 August with 4DMedical anticipating commencement of trading on the ASX under the ticker code ‘4DX’ on 14 August 2020.